Indivior Pharmaceuticals (INDV) Change in Receivables (2024 - 2026)

Indivior Pharmaceuticals' Change in Receivables history runs 3 years deep, the most recent figure standing at $20.0 million for Q1 2026.

• On a quarterly basis, Change in Receivables rose 281.82% year-over-year to $20.0 million in Q1 2026; TTM through Mar 2026 was $28.0 million, a 566.67% increase from a year earlier, with the FY2025 full-year figure at -$3.0 million, down 400.0% from the prior year.
• Change in Receivables advanced to $20.0 million in Q1 2026 per INDV's latest filing, from -$6.0 million in the prior quarter.
• Across five years, Change in Receivables topped out at $20.0 million in Q1 2026 and bottomed at -$11.0 million in Q1 2025.
• The 3-year median for Change in Receivables is -$4.0 million (2024), against an average of $2.0 million.
• Biggest YoY gain for Change in Receivables was 300.0% in 2025; the steepest drop was 250.0% in 2025.
• Year by year, Change in Receivables stood at $4.0 million in 2024, then slumped by 250.0% to -$6.0 million in 2025, then jumped by 433.33% to $20.0 million in 2026.
• Per Business Quant, the three latest INDV Change in Receivables figures stand at $20.0 million (Q1 2026), -$6.0 million (Q4 2025), and $18.0 million (Q3 2025).